1 completed, 1 suspended. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Suspended 1 |
Follow GV-971: new trials by email Literature Review of GV-971 trials Research Report on GV-971
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease GV-971, Placebo - Alzheimer Disease | Phase 3 | Suspended | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | 2046 | 2020-10-27 | 2022-11-23 |
| An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease Sodium oligo-mannurarate 900mg, Placebo - Mild to Moderate Alzheimer Disease, Cognitive Impairment | Phase 3 | Completed | Shanghai Greenvalley Pharmaceutical Co., Ltd. | 818 | 2014-04-01 | 2018-10-10 |
Alzheimer Disease (1) · Cognitive Dysfunction (1)
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. (1) · Shanghai Greenvalley Pharmaceutical Co., Ltd. (1)
China (2) · Australia (1) · Canada (1) · Czechia (1) · France (1) · Hong Kong (1) · Netherlands (1) · Poland (1) · Taiwan (1) · United States (1)